Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study in moderately to severely active ulcerative colitis (UC), marking what the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results